CYT107

DRUG7 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Cytheris SA, M.D. Anderson Cancer Center, Revimmune, National Cancer Institute (NCI)

Conditions

COVID-19HIVIdiopathic CD4+ T-LymphocytopeniaKaposi SarcomaLymphocytopeniaSepsis, SevereUmbilical Cord Blood Transplant

Phase 1

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

TerminatedNCT00839436

National Institute of Allergy and Infectious Diseases (NIAID)Idiopathic CD4+ T-Lymphocytopenia

Start: 2009-02-28End: 2014-09-30Updated: 2015-10-15

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

WithdrawnNCT03600896

M.D. Anderson Cancer CenterUmbilical Cord Blood Transplant

Start: 2018-11-30End: 2024-11-30Updated: 2019-01-10

Phase 2

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders

TerminatedNCT01241643

Start: 2010-09-30End: 2013-06-30Updated: 2013-07-25

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

TerminatedNCT03821038

RevimmuneSepsis, Severe

Start: 2019-06-01End: 2021-10-06Updated: 2021-10-27

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

TerminatedNCT04426201

RevimmuneCOVID-19, Lymphocytopenia

Start: 2020-12-20End: 2022-06-30Updated: 2024-04-11

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

TerminatedNCT04442178

RevimmuneCOVID-19, Lymphocytopenia

Start: 2020-09-15End: 2022-03-30Updated: 2022-04-08

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

RecruitingNCT07308886

National Cancer Institute (NCI)Kaposi Sarcoma

Start: 2026-04-08End: 2037-01-31Target: 55Updated: 2026-08-25

Related Papers

A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.

2025-02-046 citations

Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial.

2023-03-1251 citations

Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients

Annals of Intensive Care2022-03-0424 citations

Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies

Clinical Infectious Diseases2016-02-0777 citations

Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia

Blood2015-12-1780 citations